Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Oct;31(5):752-61.
doi: 10.1007/s10875-011-9557-z. Epub 2011 Jun 15.

Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency

Michael Borte  1 , Malgorzata Pac, Margit Serban, Teresa Gonzalez-Quevedo, Bodo Grimbacher, Stephen Jolles, Othmar Zenker, Jutta Neufang-Hueber, Bernd Belohradsky
Affiliations
Clinical Trial

Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency

Michael Borte et al. J Clin Immunol. 2011 Oct.

Abstract

Subcutaneous IgG treatment for primary immunodeficiencies (PI) is particularly well suited for children because it does not require venous access and is mostly free of systemic adverse events (AEs). In a prospective, open-label, multicenter, single-arm, Phase III study, 18 children and five adolescents with PI were switched from previous intravenous (IVIG) or subcutaneous (SCIG) IgG treatment to receive dose-equivalent, weekly subcutaneous infusions of Hizentra(®) for 40 weeks. Mean IgG trough levels were maintained in patients previously on SCIG, or increased in those previously on IVIG, regardless of age. No serious bacterial infections were reported during the efficacy period of the study. The rates of non-serious infections were 4.77 (children) and 5.18 (adolescents) infections per patient per year. Related AEs were observed in seven children (38.9%) and two adolescents (40%). Three serious AEs and two AEs leading to discontinuation (all unrelated) were reported in children. Hizentra(®) is an effective and well-tolerated treatment for pediatric patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Individual median serum IgG trough levels before and during the study. Median values were calculated for each patient for pre-study IgG levels and IgG levels measured before Infusions 12 to 17 (efficacy period; primary efficacy endpoint) and before Infusions 12 to 41 (entire study period)
See this image and copyright information in PMC

References

    1. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28:413–37. doi: 10.1016/j.iac.2008.01.008. - DOI - PMC - PubMed
    1. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med. 2000;343:1313–24. doi: 10.1056/NEJM200011023431806. - DOI - PubMed
    1. Chapel H, Geha R, Rosen F. Primary immunodeficiency diseases: an update. Clin Exp Immunol. 2003;132:9–15. doi: 10.1046/j.1365-2249.2003.02110.x. - DOI - PMC - PubMed
    1. Ochs HD, Smith CIE, Puck JM. Primary immunodeficiency diseases: a molecular and genetic approach. 2. New York: Oxford University Press Inc, USA; 2007.
    1. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372:489–502. doi: 10.1016/S0140-6736(08)61199-X. - DOI - PubMed

Publication types

MeSH terms